Kaken Pharmaceutical Co. Ltd
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regrot… Read more
Kaken Pharmaceutical Co. Ltd (KKPCF) - Total Assets
Latest total assets as of December 2025: $176.59 Billion USD
Based on the latest financial reports, Kaken Pharmaceutical Co. Ltd (KKPCF) holds total assets worth $176.59 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kaken Pharmaceutical Co. Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Kaken Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kaken Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Kaken Pharmaceutical Co. Ltd's total assets of $176.59 Billion consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.4% |
| Accounts Receivable | $21.18 Billion | 11.1% |
| Inventory | $19.02 Billion | 10.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.25 Billion | 2.8% |
| Goodwill | $14.04 Billion | 7.4% |
Asset Composition Trend (2005–2025)
This chart illustrates how Kaken Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kaken Pharmaceutical Co. Ltd's current assets represent 58.5% of total assets in 2025, a decrease from 59.1% in 2005.
- Cash Position: Cash and equivalents constituted 28.4% of total assets in 2025, up from 15.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 11.1% of total assets.
Kaken Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Kaken Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Kaken Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Kaken Pharmaceutical Co. Ltd generates 0.49x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Kaken Pharmaceutical Co. Ltd generates $7.32 in net profit.
Kaken Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.09 | 4.38 | 5.34 |
| Quick Ratio | 3.21 | 3.78 | 4.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.98 Billion | $ 98.86 Billion | $ 92.39 Billion |
Kaken Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Kaken Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.04 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.0% |
| Total Assets | $190.42 Billion |
| Market Capitalization | $859.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kaken Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Kaken Pharmaceutical Co. Ltd's assets grew by 11.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kaken Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total assets of Kaken Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $190.42 Billion | +10.95% |
| 2024-03-31 | $171.62 Billion | +3.18% |
| 2023-03-31 | $166.33 Billion | +0.69% |
| 2022-03-31 | $165.18 Billion | +1.13% |
| 2021-03-31 | $163.33 Billion | +3.46% |
| 2020-03-31 | $157.88 Billion | +1.21% |
| 2019-03-31 | $155.99 Billion | +2.34% |
| 2018-03-31 | $152.42 Billion | +12.85% |
| 2017-03-31 | $135.06 Billion | +1.56% |
| 2016-03-31 | $132.99 Billion | +15.51% |
| 2015-03-31 | $115.14 Billion | +8.14% |
| 2014-03-31 | $106.47 Billion | -2.25% |
| 2013-03-31 | $108.91 Billion | +3.62% |
| 2012-03-31 | $105.11 Billion | +6.72% |
| 2011-03-31 | $98.49 Billion | +3.57% |
| 2010-03-31 | $95.10 Billion | +0.63% |
| 2009-03-31 | $94.50 Billion | +0.69% |
| 2008-03-31 | $93.86 Billion | -6.98% |
| 2007-03-31 | $100.90 Billion | +2.19% |
| 2006-03-31 | $98.74 Billion | -9.04% |
| 2005-03-31 | $108.55 Billion | -- |